ClinicalTrials.gov
ClinicalTrials.gov Menu

Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (HepCOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00473993
Recruitment Status : Completed
First Posted : May 16, 2007
Last Update Posted : February 16, 2009
Sponsor:
Collaborator:
University of Zurich
Information provided by:
Seidenberg, Arztpraxis A., M.D.

Brief Summary:

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.


Condition or disease
Hepatitis C, Chronic Substance Abuse Treatment Centers Opioid-Related Disorders

Detailed Description:
www.seidenberg.ch/hepcop.pdf

Study Type : Observational
Time Perspective: Retrospective
Official Title: Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung
Study Start Date : July 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Study Population
Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland
Criteria

Inclusion Criteria:

  • Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473993


Sponsors and Collaborators
Seidenberg, Arztpraxis A., M.D.
University of Zurich
Investigators
Study Director: André Seidenberg, Dr.med. research fellow EHAM, University of Zurich

Additional Information:
ClinicalTrials.gov Identifier: NCT00473993     History of Changes
Other Study ID Numbers: HepCOP Zurich
First Posted: May 16, 2007    Key Record Dates
Last Update Posted: February 16, 2009
Last Verified: May 2007

Keywords provided by Seidenberg, Arztpraxis A., M.D.:
Hepatitis C
Opioid Maintenance Treatment
Methadone
Buprenorphine
Heroin
Interferon, pegylated

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Substance-Related Disorders
Hepatitis C, Chronic
Opioid-Related Disorders
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Chemically-Induced Disorders
Mental Disorders
Hepatitis, Chronic